Lowe Brockenbrough & Co. Inc. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,170 shares of the medical research company’s stock after acquiring an additional 127 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Amgen were worth $4,786,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the business. Financial Advisors Network Inc. grew its stake in Amgen by 6.2% in the first quarter. Financial Advisors Network Inc. now owns 4,457 shares of the medical research company’s stock valued at $714,000 after acquiring an additional 261 shares during the period. Brighton Jones LLC lifted its holdings in shares of Amgen by 83.2% in the first quarter. Brighton Jones LLC now owns 2,642 shares of the medical research company’s stock valued at $433,000 after purchasing an additional 1,200 shares in the last quarter. Aristotle Capital Management LLC lifted its holdings in shares of Amgen by 2.7% in the first quarter. Aristotle Capital Management LLC now owns 1,441,342 shares of the medical research company’s stock valued at $236,481,000 after purchasing an additional 37,721 shares in the last quarter. Hutchens Investment Management Inc bought a new stake in shares of Amgen in the first quarter valued at about $1,074,000. Finally, Green Square Capital LLC lifted its holdings in shares of Amgen by 1,337.1% in the first quarter. Green Square Capital LLC now owns 41,344 shares of the medical research company’s stock valued at $6,783,000 after purchasing an additional 38,467 shares in the last quarter. 78.14% of the stock is owned by hedge funds and other institutional investors.
AMGN has been the topic of a number of research reports. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $189.00 price target on shares of Amgen in a report on Friday, May 19th. Jefferies Group LLC restated a “hold” rating and issued a $180.00 price target on shares of Amgen in a report on Monday, May 22nd. UBS AG restated a “neutral” rating and issued a $174.00 price target (down from $175.00) on shares of Amgen in a report on Monday, May 22nd. BMO Capital Markets restated a “buy” rating and issued a $198.00 price target (down from $200.00) on shares of Amgen in a report on Monday, May 22nd. Finally, Leerink Swann set a $159.00 price target on Amgen and gave the company a “hold” rating in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen has a consensus rating of “Buy” and an average target price of $186.04.
Amgen Inc. (NASDAQ AMGN) traded down 1.43% during trading on Wednesday, reaching $188.27. The company’s stock had a trading volume of 1,424,952 shares. Amgen Inc. has a one year low of $133.64 and a one year high of $190.94. The company has a 50-day moving average of $173.95 and a 200 day moving average of $168.82. The firm has a market cap of $137.38 billion, a PE ratio of 17.15 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the prior year, the company posted $2.84 earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts expect that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.
ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/2889367/amgen-inc-amgn-shares-bought-by-lowe-brockenbrough-co-inc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.